PUBLICATION AND RESOURCES

PUBLICATIONS

5.3.2021 | Clinical Cancer Research
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Landon C. Brown1, Susan Halabi1,2, Joseph D. Schonhoft3, Qian Yang2, Jun Luo4, David M. Nanus5, Paraskevi Giannakakou5, Russell Z. Szmulewitz6, Daniel C. Danila5,7, Ethan S. Barnett7, Emily A. Carbone7, Jimmy L. Zhao7, Patrick Healy8, Monika Anand1, Audrey Gill3, Adam Jendrisak3, William R. Berry1, Santosh Gupta9, Simon G. Gregory9, Richard Wenstrup3, Emmanuel S. Antonarakis10, Daniel J. George1, Howard I. Scher5,7, and Andrew J. Armstrong1
5.3.2021 | Clinical Cancer Research
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

H.I. Scher a,b,,1, A.J. Armstrong c,*,1, J.D. Schonhoft d, A. Gill d, J.L. Zhao a, E. Barnett a, E. Carbone a, J.Lud, E.S. Antonarakis e, J. Luo e, S. Tagawa b, C.H. dos Anjos a, Q. Yang f, D. George c, R. Szmulewitz f,g, D.C. Danila a,b, R. Wenstrup d, M. Gonen a,2,
S. Halabi c,f,2
5.3.2021 | Clinical Cancer Research
Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer

Joseph D. Schonhoft1, Jimmy L. Zhao2,3, Adam Jendrisak1, Emily A. Carbone4, Ethan S. Barnett4, Melanie A. Hullings4,5, Audrey Gill1, Ramsay Sutton1, Jerry Lee1, Angel E. Dago1, Mark Landers1, Samuel F. Bakhoum3,6, Yipeng Wang1, Mithat Gonen7, Ryan Dittamore1, and Howard I. Scher2,8
10.28.2020 | JCO Precision Oncology
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM1; Jun Luo, PhD2; David M. Nanus, MD3; Paraskevi Giannakakou, PhD3; Russell Z. Szmulewitz, MD4; Daniel C. Danila, MD3,5; Patrick Healy, MS; Monika Anand, PhD1; William R. Berry, MD1; Tian Zhang, MD1; Michael R. Harrison, MD1; Changxue Lu, MM, PhD2; Yan Chen, BM, PhD2; Giuseppe Galletti, MD, PhD3; Joseph D. Schonhoft, PhD7; Howard I. Scher, MD5; Richard Wenstrup, MD7; Scott T. Tagawa, MD3; Emmanuel S. Antonarakis, MD2,8; Daniel J. George, MD1; and Susan Halabi, PhD8
FULL PUBLICATION LIST

Resources

SCIENTIFIC POSTERS

12.9.2021
Circulating tumor cells (CTCs), CTC heterogenity and distinct morphological CTC phenotypes predict worse survival in metastatic breast cancer (MBC)
2.11.2021
Development and Validation of Circulating Tumor Cell Enumeration (Epic Sciences) as a Prognostic Biomarker in Men with Metastatic Castration Resistant Prostate Cancer.
2.11.2021
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
12.18.2020
Pilot Trial of Priming With Oral TAK-228 and TAK-117 (PIKTOR) to Increase DNA Damage Repair Deficiency Followed By Cisplatin and Nab Paclitaxel in Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer Patients.
All SCIENTIFIC POSTERS

PACKAGE INSERTS

AR-V7 Blood Collection Kit Package Insert (Kit FM-00049 and FM-00076)
CE Mark Blood Collection Kit Package Insert (Kit FM-000107)
CTC Liquid Biopsy Blood Collection Kit Requisition Form (LBL-00081)
ALL INSERTS

EPIC PODCAST: FEATURED

6.13.2019
EPISODE 02 | LAUREN LEIMAN

In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.

Listen Now
MORE EPISODES